Bolt Biotherapeutics, Inc.
- Jurisdiction
United States - LEI
254900W0P77PQ6B8OY50 - ISIN
US0977021049 (BOLT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
1
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. Read full profile
Fundamentals
- Net revenue
€3.55M - Gross margin
100.0% - EBIT
-€46.64M - EBIT margin
-1,312.3% - Net income
-€43.26M - Net margin
-1,217.0%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
- Last dividend amount
-
$0.09 - Ex date
-
- Payment date
-
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 17, 2024 (Q1 2024)